Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
JOHN P COOKE · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $333,348 — PROJECT SUMMARY RNA vaccines have quicker development timelines and are simpler to manufacture than traditional vaccines. Combining this strength of RNA technology with protein engineering, they hold the potential to generate highly efficacious vaccines rapidly that can target and harness the immune…
Scott F Michael · COLLEGE AT OSWEGO · 2023 · $158,723 — PROJECT SUMMERY Most currently available vaccines, especially live and mRNA-based COVID-19 vaccines, are temperature sensi- tive and require stringent cold-chain maintenance, entailing their storage and distribution at recommended tem- peratures from production to administration. This necessity impo…
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2023 · $1,357,000 — Summary (Overall) San Antonio has a rich tradition of excellence in the field of Medical Mycology, including Coccidioidomycosis, also referred to as Valley Fever. These infections affect hundreds of thousands of healthy and immunocompromised individuals in the endemic areas of the arid Southwest U.S…
Adolfo Garcia-Sastre · JACKSON LABORATORY · 2023 · $2,195,905 — PROJECT SUMMARY The WHO estimates that annual epidemics of influenza result in 3-5 million cases of severe illness and 300,000- 500,000 deaths. 90% of influenza-related deaths occur in older adults despite widespread vaccination programs with vaccines tailored for this high-risk group. The estimated…
Jianrong Li · OHIO STATE UNIVERSITY · 2023 · $468,678 — Abstract This application is to renew a grant to study RNA methylation in pneumoviruses. Pneumoviridae is a new virus family, created in 2016 by elevating the paramyxoviral subfamily Pneumovirinae to family status. The Pneumoviridae family includes two medically important pathogens, human respirator…
Johannes Morstein · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $163,080 — Project Summary Significant progress in human cancer therapy in the last decade has been driven by conceptionally new approaches to treating cancer, including cancer immunotherapy, cancer nanotherapy (e.g. liposomal doxorubicin or mRNA vaccines), or new types of biologics and small molecules. I prop…
BALI PULENDRAN · STANFORD UNIVERSITY · 2023 · $2,168,222 — ABSTRACT – Overall Component In the current proposal we will use a systems vaccinology approach to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). Th…
Christopher S Anderson · UNIVERSITY OF ROCHESTER · 2023 · $101,672 — Respiratory Syncytial Virus (RSV) is the second leading cause of hospitalization in children worldwide and has been increasing appreciated as a cause of hospitalization and death in the elderly. Recent studies have shown that polyvalent vaccine formulations, mixture of antigens derived from distinct…
R. Brad Jones · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $211,875 — PROJECT SUMMARY/ABSTRACT Although modern therapies have dramatically improved the outlooks for people living with HIV they are unable to cure infection, leaving these individuals burdened by a lifelong commitment to antiretroviral (ARV) medication. For any given individual, maintaining lifelong adhe…
Guido Ferrari · DUKE UNIVERSITY · 2023 · $5,902,563 — ABSTRACT The ultimate goal of the proposed studies is to contribute to ending the HIV/AIDS epidemic. It has been four decades since the start of the HIV/AIDS epidemic and a protective vaccine or functional cure has been elusive. In 2020, there was an estimated 37.6 million people living with HIV. D…
Yang Xu · LUNA LABS USA, LLC · 2023 · $296,815 — Project Summary Significant research has gone into the development of a safe and effective vaccine for HIV-1. Although many strategies have been attempted; none has been successfully established. Even a partially effective vaccine could decrease the number of people who are infected with HIV, furthe…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2023 · $627,134 — ABSTRACT Inherited retinal dystrophies (IRDs) are a heterogenous group of orphan diseases, inherited in an autosomal dominant, recessive or X-linked pattern in addition to mitochondrial transmission, all leading to the loss of functional vision and often progressing to blindness. As a group, IRDs ar…
FENGWEI BAI · UNIVERSITY OF SOUTHERN MISSISSIPPI · 2023 · $444,000 — Summary Zika virus (ZIKV) is a mosquito-transmitted flavivirus that has caused devastating congenital Zika syndromes (CZS), including microcephaly, congenital malformation, and fetal demise in human newborns in the 2015 - 2016 epidemics. In addition, ZIKV infection can cause Guillain-Barré syndrome …
Zhijian Jake Tu · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2023 · $774,520 — Abstract Sex is critical to the survival and evolution of sexually reproducing organisms including mosquitoes. A dominant male-determining factor (M factor) is the primary signal that controls sex-determination in mosquitoes. Nix, the M factor in the yellow fever mosquito Aedes aegypti, is the first…
DAVID B. WEINER · INTERNATIONAL SOCIETY OF VACCINES · 2023 · $5,000 — Project Summary / Abstract The International Society for Vaccines (ISV) is a not-for-profit membership organization founded in 1992 with members from 44 countries, holding annual congresses since 2007. With the ISV Annual Congress, attended by member and non-member participants from 5 continents, th…
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2023 · $561,330 — This application is to extend a MERIT award to study RNA synthesis in minus-strand RNA viruses. Nonsegmented negative-sense (NNS) RNA viruses include some of the most significant human pathogens that are an ongoing threat to US public health. For measles, mumps and rabies there are licensed vaccines…
Xiaorong Lin · UNIVERSITY OF GEORGIA · 2023 · $166,248 — Cryptococcus neoformans and C. gattii cause life threatening cryptococcal meningoencephalitis, the most common fungal infection of the central nervous system in the world today. The 12-month mortality rate for individuals with cryptococcal meningoencephalitis is 60% even with the current antifungal …
THOMAS MELENDY · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2023 · $199,375 — Project Summary/Abstract: Effective antivirals are sorely needed against SARS CoV-2 (CoV2), and coronaviruses (CoV) in general. Screening systems for drugs targeting CoV2 enzymes usually involve screening against purified enzymes. This can be technically challenging, and the vast majority of inhibit…
YASUHIRO SUZUKI · UNIVERSITY OF KENTUCKY · 2023 · $459,000 — Chronic infection with Toxoplasma gondii can reactivate and cause life-threatening toxoplasmic encephalitis in AIDS patients and other immunocompromised individuals. The basis of persistence of this chronic infection is the tissue cyst. Thus, eliminating T. gondii cysts from chronically infected ind…
MATTHEW TIRRELL · UNIVERSITY OF CHICAGO · 2023 · $797,003 — Project Summary This R01 proposal outlines a research plan which uses targeted nanomedicine to enhance disease- modifying molecular mechanisms both in the acute injurious phase and in the subsequent chronic fibrotic phase of viral-induced pneumonitis. The overall goal of this proposal is to use nan…